NCT02079207View on ClinicalTrials.gov

Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

767

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

March 31, 2015

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

NBP606

13-valent peumococcal conjugate vaccine(13vPnC)

BIOLOGICAL

Prodiax-23

23-valent peumococcal polysaccharide vaccine(23vPS)

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT02079207 - Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine | Biotech Hunter | Biotech Hunter